RT Journal Article
SR Electronic
T1 Prevalence of Late-Stage Parkinson’s Disease in the US Health Care System: Insights from TriNetX
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.29.24301955
DO 10.1101/2024.01.29.24301955
A1 De Jesus, Sol
A1 Daya, Annika
A1 Blumberger, Liba
A1 Lewis, Mechelle M.
A1 Leslie, Doug
A1 Tabbal, Samer D.
A1 Dokholyan, Rachel
A1 Snyder, Amanda M.
A1 Mailman, Richard B.
A1 Huang, Xuemei
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.01.29.24301955.abstract
AB Background Patients in late-stage Parkinson’s disease (PDLS) are caregiver dependent, have low quality of life, and higher health care costs.Objective To estimate the prevalence of PDLS patients in the current United States (US) health care system.Methods We downloaded the 2010-2022 data from the TriNetX Diamond claims network that consists of 92 USA health care sites. PD was identified using standard diagnosis codes, and PDLS was identified by the usage of wheelchair dependence, personal care assistance and/or presence of diagnoses of dementia. Age of PDLS identification, and survival information are obtained and stratified by demographic and the disability subgroups.Results We identified 1,031,377 PD patients in the TriNetX database. Of these, 18.8% fit our definition of PDLS (n=194,297), and 10.2% met two or more late-stage criteria. Among all PDLS, the mean age of PDLS identification was 78.1 (±7.7), and 49% were already reported as deceased. PDLS patients were predominantly male (58.5%), with similar distribution across PDLS subgroups. The majority did not have race (71%) or ethnicity (69%) information, but for the available information, >90% (n=53,162) were white, 8.2% (n=5,121) Hispanic/Latino, 7.8% (n=4,557) black, and <0.01% (n=408) Asian. Of the PDLS cohort, 71.6% identified with dementia, 12.9% had personal care assistance, and 4.8% were wheelchair bound.Conclusions Late-stage patients are a significant part of PD landscape in the current US healthcare system, and largely missed by traditional motor-based disability staging. It is imperative to include this population as a clinical, social, and research priority.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Trinetx (https://live.trinetx.com/)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript